Abstract: A processing device to be used in an inspection apparatus for optical inspection of samples is configured to be used with an optical inspection device, to be communicatively coupled to a user interface, to receive input data from the user interface and/or from the optical inspection device, and to provide output data to the user interface, and to be communicatively coupled to at least one other processing device to allow data transfer. The processing device is configured as a master unit, and the at least one other processing device is configured as a slave unit. The processing device is further configured to provide a data storage for storing data received as input and/or to be provided as output, and to allow the at least one other processing device to access the data storage to store data and/or to retrieve data.

Abstract: A processing device to be used for optical inspection of samples is configured to be communicatively coupled to a camera of an optical inspection device and to a user interface, to receive input data from the user interface and/or from the camera, to provide output data to the user interface, to be communicatively coupled to a storage device, to provide instructions, by accessing instruction data stored at the storage device, for optical quality inspection of samples to be performed by a user via the user interface. The instructions include instructions regarding what kind of optical quality inspection to be performed on which sample. The processing device is further configured to receive quality report data from the optical quality inspection via the user interface, and/or image data of images acquired by the camera, and to store the quality report data and/or the image data in the storage device.

Abstract: The present invention provides an ultra-microinjection detection and control device based on lensless imaging and a method thereof. A lensless optical liquid level sensor is used to measure a change of a liquid level in an injection needle. A microinjection control unit is used to track the change of the liquid level and correct an injection pressure of the injection pump. Transmitted light generated by a parallel light source passes through a transparent glass tube of the injection needle. Then the transmitted light passes through a light filtering film to reduce the intensity of the parallel light source to a photosensitivity range of a micro linear array image sensor chip. Finally, the transmitted light enters the micro linear array image sensor chip, so that the micro linear array image sensor chip measures the change of the liquid level in the injection needle.

Abstract: A compound of Formula I compound—Ovatodiolide which is safe and effective to use in a pharmaceutical composition for inhibition of SARS-CoV-2 is provided. The pharmaceutical composition comprising a safe and effective amount of a compound of Formula I compound—Ovatodiolide or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier, which has great potential to treat SARS-CoV-2 induced COVID-19 based on a safe and effective amount of a compound of Formula I compound—Ovatodiolide.

Abstract: Provided herein are modified anti-SARS-COV-2 antibodies or antigen binding fragments thereof having extended half life and optimized immune activities. Disclosed herein is also directed to pharmaceutical compositions comprising the same and a method for treating or preventing a disease in human patients that is caused by or related to the infection of SARS-COV-2.

Abstract: Provided herein are modified anti-SARS-COV-2 antibodies or antigen binding fragments thereof having extended half life and optimized immune activities. Disclosed herein is also directed to pharmaceutical compositions comprising the same and a method for treating or preventing a disease in human patients that is caused by or related to the infection of SARS-COV-2.

Abstract: Provided herein are modified anti-SARS-COV-2 antibodies or antigen binding fragments thereof having extended half life and optimized immune activities. Disclosed herein is also directed to pharmaceutical compositions comprising the same and a method for treating or preventing a disease in human patients that is caused by or related to the infection of SARS-COV-2.

Abstract: The present invention provides an ultra-microinjection detection and control device based on lensless imaging and a method thereof. A lensless optical liquid level sensor is used to measure a change of a liquid level in an injection needle. A microinjection control unit is used to track the change of the liquid level and correct an injection pressure of the injection pump. Transmitted light generated by a parallel light source passes through a transparent glass tube of the injection needle. Then the transmitted light passes through a light filtering film to reduce the intensity of the parallel light source to a photosensitivity range of a micro linear array image sensor chip. Finally, the transmitted light enters the micro linear array image sensor chip, so that the micro linear array image sensor chip measures the change of the liquid level in the injection needle.

Abstract: The present invention includes the efficient dispersion and high loading of fillers in a thermoplastic polymer matrix. In a first general embodiment, the present invention includes a method wherein fillers are first synthesized and dispersed in a liquid monomer. The liquid monomer is then polymerized to a solid. The nanofillers may be silver nanoparticle/nanowire fillers. Ethylene glycol may serve as a solvent, reducing agent as well as precursor monomer for polymerization. In a second general embodiment, the present invention includes a method wherein fillers may be separately synthesized (or obtained commercially) and then added and dispersed in a liquid monomer. The liquid monomer is then polymerized to a solid. In a third general embodiment, a composite is synthesized using interfacial polycondensation. This is accomplished by aggressive mixing of two solvents during the reaction. The aggressive mixing forms microdroplets (i.e.

Abstract: The present invention includes the efficient dispersion and high loading of fillers in a thermoplastic polymer matrix. In a first general embodiment, the present invention includes a method wherein fillers are first synthesized and dispersed in a liquid monomer. The liquid monomer is then polymerized to a solid. The nanofillers may be silver nanoparticle/nanowire fillers. Ethylene glycol may serve as a solvent, reducing agent as well as precursor monomer for polymerization. In a second general embodiment, the present invention includes a method wherein fillers may be separately synthesized (or obtained commercially) and then added and dispersed in a liquid monomer. The liquid monomer is then polymerized to a solid. In a third general embodiment, a composite is synthesized using interfacial polycondensation. This is accomplished by aggressive mixing of two solvents during the reaction. The aggressive mixing forms microdroplets (i.e.

Abstract: The present invention provides methods of treating drug-resistant HIV infections especially of HIV strains that are resistant to infusion inhibitors, such as T20.

Abstract: Methods are provided for sensitively quantitating at least one pre-selected DNA sequence in a biological sample utilizing hybridization methodology, the method employing as an internal standard an infectious bacteriophage particle comprising a detectable target DNA sequence other than that present in the pre-selected DNA sequence or in DNA quantitated from the biological sample, and as an external standard, an infectious bacteriophage particle comprising at least the pre-selected DNA sequence.

Abstract: The invention identifies polypeptide biomarkers of disease progression or nonprogression by comparative protein profiling of samples from progressors and nonprogressors subpopulations of a population exposed to the pathogen or sharing a risk facto causing the disease. The polypeptides, their ligands, and modulators find use as diagnostic, prognostic, and therapeutic agents.

Abstract: The present invention relates to inhibition of viruses, e.g., HIV, using defensins. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, nucleic acids, antisense nucleic acids, and ribozymes, that increase naturally occurring defensin expression or activity, thereby inhibiting HIV in a cell; as well as to the use of expression profiles and compositions in diagnosis and prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.

Abstract: Methods for identifying genetic sequences useful as genomic equivalent markers for organisms are described. The method involves determining the ratio of the absolute number of copies of wild type and mutant amplicons in a number of samples from organisms heterozygous for the mutation. After establishing the number of copies of a particular genetic sequence per genome, the sequence may be used as a measure of the number of genomes per sample, in order to normalize the analysis of another target sequence to abundance per cell. By way of example, the CCR5 gene was shown to be present at 2 copies per genome, and used to measure the number of copies per cell of HIV-1 provirions, human herpesvirus-8, and &agr; deletion circles, a measure of recent thymic emigrants for assessing immune reconstitution.